Using miR-125b in the Prediction of Aromatase Inhibitors Resistance in Metastatic Breast Cancer

Main Article Content

Ashraf Zedain
Hosney Badrway
Ahmed Refaat
Dina Ismail Abd El Razik
Ahmed Mahran
Abeer Ibrahim


Background: Several studies investigated the miRNAs in cancer trying to assess the prognosis or to predict the response to certain treatment .One of these miRNAs are miR 125b , it was suggested by previous results as a good marker for prediction of aromatase inhibitors (AI) response. So, this study was conducted to assess the value using miRNA125b as a predictive factor to AI response.

Patients and Methods: A total of 90 patients of postmenopausal HR+ve metastatic breast cancer who attended to medical oncology department outpatient’s clinic in SECI, Assiut university Egypt, from May 2017 to September 2018. Patients presented with metastasis at diagnosis as well as patients who relapsed only after 3 years of adjuvant hormonal treatment with SERM were included. All patients received AI as first line treatment for metastatic, miRNA 125b was isolated from peripheral blood samples and measured by using (q PCR).The response of patients was assessed by RECIST criteria and correlated with its expression levels.

Results: Expression of the miR125-b was significantly higher in patients than control p= 0.000. However, no significant difference in its expression between those with single of multiple metastases or even between the site of metastases. We didn’t find also any significant difference in response p=0.648 and survival either PFS p=0.406 or OS p=0.384 between those patients with high expression vs. low expression.

Conclusion: Our results suggest that miR125b could be used as a diagnostic marker as it is significantly increased in patients than control. However, we don’t recommend using miR125b as a marker to predict the AI resistance as further studies with large sample size are needed to confirm these results.

Breast cancer, miR125b, predictive factor, aromatase inhibitors.

Article Details

How to Cite
Zedain, A., Badrway, H., Refaat, A., Razik, D. I. A. E., Mahran, A., & Ibrahim, A. (2020). Using miR-125b in the Prediction of Aromatase Inhibitors Resistance in Metastatic Breast Cancer. Journal of Cancer and Tumor International, 10(3), 1-9.
Original Research Article


Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline update on ovarian suppression. J Clin Oncol. 2016; 34(14):1689-701.

DOI: 10.1200/JCO.2015.65.9573

Epub 2016 Feb 16.

Cavazzoni A, Bonelli MA, Fumarola C, La Monica S, Airoud K, Bertoni R, et al. Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Lett. 2012;323:77–87.

DOI: 10.1016/j.canlet.2012.03.034

Epub 2012 Apr 3.

Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer. 2010;126:545–62.


Campos-Parra AD, Mitznahuatl GC, Pedroza-Torres A, Romo RV , Reyes FI, López-Urrutia E, Pérez-Plasencia C. Micro-RNAs as potential predictors of response to breast cancer systemic therapy: Future clinical implications. Int. J. Mol. Sci. 2017;18(6):1182.


Macedo LF, Sabnis GJ, Goloubeva OG, Brodie A. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res. 2008;68: 3516–22.


Vilquin P, Villedieu M, Grisard E, Larbi SB, Ghayad SE, Heudel PE, et al. Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor. Int J Cancer. 2013;133:1589–602.


Epub 2013 May 2.

Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–47.

DOI: 10.1146/annurev-med-0709091829-17

Ghayad SE, Bieche I, Vendrell JA, Keime C, Lidereau R, Dumontet C, et al. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008;99:1992–2003.

DOI: 10.1111/j.1349-7006.2008.00955.x

Le Romancer M, Poulard C, Cohen P, Sentis S, Renoir JM, Corbo L. Cracking the estrogen receptor’s posttranslational code in breast tumors. Endocr Rev. 2011;32: 597–622.

DOI: 10.1210/er.2010-0016

Epub 2011 Jun 15.

Nicholson RI, Staka C, Boyns F, Hutcheson IR, Gee JM. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr Relat Cancer. 2004;11: 623–41.

DOI: 10.1677/erc.1.00778

Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302:1–12.

DOI: 10.1016/j.ydbio.2006.08.028

Erson AE, Petty EM. MicroRNAs in development and disease. Clin Genet. 2008;74:296–306.


Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449:682–8.


Casey MC, Sweeney KJ, Brown JAL, Kerin MJ. Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer. Int J Cancer. 2016;139:12–22.


Vilquin P, Donini CF, Villedieu M, Grisard E, Corbo L, Bachelot T, Vendrell JA, Cohen PA. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Breast Cancer Res. 2015; 30;(17):13-22.

DOI: 10.1186/s13058-015-0515-1

McAnena P, Lowery A, Kerin MJ. Role of micro-RNAs in breast cancer surgery. Br J Surg. 2018;105:19–30.


Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: Approaches and considerations. Nat Rev Genet. 2012;13: 358–69.

DOI: 10.1038/nrg3198

Freedman JE, Gerstein M, Mick E, Rozowsky J, Levy D, Kitchen R, et al. Diverse human extracellular RNAs are widely detected in human plasma. Nat Commun. 2016;7:11106.

DOI: 10.1038/ncomms11106

Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Kerin MJ, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast Cancer. Ann Surg. 2010;251:499–505.

DOI: 10.1097/SLA.0b013e3181cc939f

Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer. 2013;132:1602–12.


Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008; 105:10513–8.


Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2): 228-47.

DOI: 10.1016/j.ejca.2008.10.026

Allred C, Harvely J, Berado M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1999;11:155–168.

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53: 457-81.

Kassem NM, Makar WS, Kassem HA, Talima S, Tarek M, Hesham H, El-Desouky MA. Circulating miR-34a and miR-125b as promising non invasive biomarkers in Egyptian locally advanced breast cancer patients. Asian Pac J Cancer Prev. 2019;20(9): 2749-2755.

DOI: 10.31557/APJCP.2019.20.9.2749

Han J, Jiang Y, Zhang C, et al. A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer. Ann Surg Treat Res. 2017; 92:55–66.


Wang H, Tan G, Dong L, et al. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One. 2012;7:34210.


Bailey ST, Westerling T, Brown M. Loss of estrogen-regulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer. Cancer Res. 2015;75:436-45.

DOI: 10.1158/0008-5472.CAN-14-1041

Hoppe R, Fan P, Büttner F, Winter S, Tyagi AK, Cunliffe H, Jordan VC, Brauch H. Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer Oncotarget. 2016;7(44):71235-71254.

DOI: 10.18632/oncotarget.12103

Yang Z, Han Y, Cheng K, Zhang G, Wang X. miR-99a directly targets the mTOR signaling pathway in breast cancer side population cells. Cell Prolif. 2014;47:587-95.

DOI: 10.1111/cpr.12146

Epub 2014 Oct 27.

Qian P, He XC, Paulson A, Li Z, Tao F, Perry JM, Guo F, Zhao M, Zhi L, Venkatraman A, Haug JS, Parmely T, Li H, et al. The Dlk1-Gtl2 locus preserves LT-HSC function by inhibiting the PI3K-mTOR pathway to restrict mitochondrial metabo-lism. C Stem Cell. 2016;18(2):214-28.

DOI: 10.1016/j.stem.2015.11.001

Epub 2015.